Collegium Pharmaceutical (NASDAQ:COLL) has received mixed analyst ratings over the past three months, with a recent upward trend in price targets to an average of $39.75, indicating a 7.43% increase from the previous $37.00. Analysts from Needham, Truist Securities, and Piper Sandler have maintained or raised their ratings, reflecting positive market dynamics and company performance. Collegium's financial performance shows strong revenue growth, profitability, and efficient asset management, with a market capitalization below industry averages but impressive growth and net margins.